Ixazomib-associated cardiovascular adverse events in multiple myeloma: a systematic review and meta-analysis

Abstract

Prolonged survival and expanded treatment options in myeloma patients have led to adverse events associated with treatment getting increased attention. This systematic review and meta-analysis aimed to determine the incidence of ixazomib–associated cardiovascular adverse events (CVAEs) and to compare the rates of ixazomib–associated CVAEs and related therapies. CVAEs were defined as heart failure, hypertension, ischemia, and arrhythmia. All-grade and high-grade CVAEs and study characteristics were recorded. A total of 266 potentially relevant articles were identified, and 246 were excluded after review. Twenty studies of 1715 patients with multiple myeloma were thus considered in this study. The estimated rates of all-grade and high-grade ixazomib associated CVAEs were 11.2 and 3.7%, respectively. Subgroup analysis showed that median age ≥65 years, none phase 1 trial and combination regimen were associated with higher rates of high-grade ixazomib associated CVAEs. Ixazomib was association with increased high-grade CVAEs risk (RR = 1.679, 95% CI: 1.078–2.615, P = 0.022). Ixazomib was associated with a significant rate of high-grade CVAEs. Future studies are needed to identify patients at high risk for high-grade CVAEs.

Keywords:

• Ixazomib
• cardiovascular adverse events
• systematic review
• meta-analysis

Acknowledgments

The authors thank Prof. Yunjiu Cheng for helpful data search and discussions.

Disclosure statement

The authors have nothing to disclose.

Author contributions

Y.L. designed and wrote the paper, and extracted the data. R.L. and J.Z. extracted the data. Y.Z. and Z.C. searched the study and did the statistical analysis.

Additional information

Funding

Special Fund of Foshan Summit Plan [2019B009].